• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血清骨保护素和核因子κB受体活化因子配体水平作为血液透析终末期肾病患者心血管钙化发生的危险因素

Serum OPG and RANKL Levels as Risk Factors for the Development of Cardiovascular Calcifications in End-Stage Renal Disease Patients in Hemodialysis.

作者信息

Spartalis Michalis, Kasimatis Efstratios, Liakou Eleni, Sampani Erasmia, Lioulios Georgios, Christodoulou Michalis, Stai Stamatia, Moysidou Eleni, Efstratiadis George, Papagianni Aikaterini

机构信息

Department of Nephrology, Aristotle University of Thessaloniki, "Hippokration" General Hospital, 54642 Thessaloniki, Greece.

出版信息

Life (Basel). 2023 Feb 6;13(2):454. doi: 10.3390/life13020454.

DOI:10.3390/life13020454
PMID:36836810
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9967106/
Abstract

Cardiovascular calcifications (CVC) are frequently observed in chronic kidney disease (CKD) patients and contribute to their cardiovascular mortality. The aim of the present study was to investigate the impact of osteoprotegerin (OPG)/Receptor Activator of NF-κΒ (RANK)/RANK ligand (RANKL) pathway in the development and evolution of CVCs in hemodialysis patients. In total, 80 hemodialysis patients were assessed for the presence of vascular (abdominal aorta and muscular arteries) calcifications and results were correlated to serum OPG and RANKL levels and the OPG/RANKL ratio. Traditional cardiovascular risk factors and mineral bone disease parameters were also estimated. The presence of VCs was also evaluated 5 years after the initiation of the study, and results were correlated to the initial serum OPG levels. Age, diabetes mellitus, coronary artery disease and OPG levels ( < 0.001) were associated with VCs, whereas RANKL levels were not. Multivariate analysis though revealed that only OPG levels were significantly associated with abdominal aorta calcifications ( = 0.026), but they were not correlated with the progression of VCs. Serum OPG levels are positively and independently associated with VCs in HD patients, but not with their progression. RANKL levels did not show any associations, whereas further studies are needed to establish the significance of OPG/RANKL ratio.

摘要

心血管钙化(CVC)在慢性肾脏病(CKD)患者中经常可见,并导致其心血管疾病死亡率升高。本研究的目的是探讨骨保护素(OPG)/核因子κB受体激活剂(RANK)/RANK配体(RANKL)通路在血液透析患者CVC发生和发展中的作用。总共对80例血液透析患者进行了血管(腹主动脉和肌性动脉)钙化情况评估,并将结果与血清OPG、RANKL水平及OPG/RANKL比值进行关联分析。同时还评估了传统心血管危险因素和矿物质骨病参数。在研究开始5年后,再次评估血管钙化情况,并将结果与初始血清OPG水平进行关联分析。年龄、糖尿病、冠状动脉疾病和OPG水平(<0.001)与血管钙化有关,而RANKL水平则无关。然而,多因素分析显示,只有OPG水平与腹主动脉钙化显著相关(=0.026),但与血管钙化进展无关。血液透析患者血清OPG水平与血管钙化呈正相关且独立相关,但与血管钙化进展无关。RANKL水平未显示出任何关联,而OPG/RANKL比值的意义还需要进一步研究来确定。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbf1/9967106/b47e94929982/life-13-00454-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbf1/9967106/49999db36d75/life-13-00454-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbf1/9967106/b47e94929982/life-13-00454-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbf1/9967106/49999db36d75/life-13-00454-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbf1/9967106/b47e94929982/life-13-00454-g002.jpg

相似文献

1
Serum OPG and RANKL Levels as Risk Factors for the Development of Cardiovascular Calcifications in End-Stage Renal Disease Patients in Hemodialysis.血清骨保护素和核因子κB受体活化因子配体水平作为血液透析终末期肾病患者心血管钙化发生的危险因素
Life (Basel). 2023 Feb 6;13(2):454. doi: 10.3390/life13020454.
2
sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients.一组男性和女性血液透析患者中的sRANKL/骨保护素复合物及生化标志物
J Endocrinol Invest. 2007 Oct;30(9):762-6. doi: 10.1007/BF03350814.
3
Osteoprotegerin and osteoprotegerin/TRAIL ratio are associated with cardiovascular dysfunction and mortality among patients with renal failure.骨保护素及骨保护素与肿瘤坏死因子相关凋亡诱导配体的比值与肾衰竭患者的心血管功能障碍及死亡率相关。
Adv Med Sci. 2016 Sep;61(2):269-275. doi: 10.1016/j.advms.2016.03.003. Epub 2016 Mar 21.
4
Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure.慢性肾衰竭患者骨保护素及核因子κB受体活化因子配体的循环水平
Clin Chem Lab Med. 2007;45(11):1498-503. doi: 10.1515/CCLM.2007.306.
5
Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.甲状旁腺激素对肾性骨病血液透析患者可溶性核因子κB受体活化因子配体-骨保护素的调节作用
Ther Apher Dial. 2009 Feb;13(1):49-55. doi: 10.1111/j.1744-9987.2009.00653.x.
6
The Effects of Initial Periodontal Therapy on the Serum Receptor Activator of Nuclear Factor-κβ Ligand/Osteoprotegerin System in Patients With Type 2 Diabetes Mellitus and Periodontitis.初始牙周治疗对2型糖尿病合并牙周炎患者血清核因子κB受体活化因子配体/骨保护素系统的影响
J Periodontol. 2016 Mar;87(3):303-11. doi: 10.1902/jop.2015.150480. Epub 2015 Nov 12.
7
Osteoprotegerin and RANKL serum levels and their relationship with serum ghrelin in children with chronic renal failure and on dialysis.慢性肾衰竭及接受透析治疗儿童的骨保护素和核因子κB受体活化因子配体血清水平及其与血清胃饥饿素的关系。
Nephron Clin Pract. 2007;105(4):c153-8. doi: 10.1159/000099005. Epub 2007 Jan 25.
8
Serum RANKL, osteoprotegerin (OPG) and RANKL/OPG ratio in children with systemic lupus erythematosus.血清 RANKL、骨保护素(OPG)及 RANKL/OPG 比值与系统性红斑狼疮患儿的相关性研究
Lupus. 2019 Sep;28(10):1233-1242. doi: 10.1177/0961203319867129. Epub 2019 Aug 12.
9
Arterial calcifications and osteoprotegerin in chronic hemodialysis patients: impact on 6-year survival.慢性血液透析患者的动脉钙化与骨保护素:对6年生存率的影响
Int Urol Nephrol. 2022 May;54(5):1135-1143. doi: 10.1007/s11255-021-02988-3. Epub 2021 Sep 9.
10
Plasma osteoprotegerin is associated with mortality in hemodialysis patients.血浆骨保护素与血液透析患者的死亡率相关。
J Am Soc Nephrol. 2006 Jan;17(1):262-70. doi: 10.1681/ASN.2005030260. Epub 2005 Nov 9.

引用本文的文献

1
Circulating osteoprotegerin levels and cardiovascular outcomes in patients with pre-dialysis chronic kidney disease: results from the KNOW-CKD study.透析前慢性肾脏病患者循环骨保护素水平与心血管结局:KNOW-CKD研究结果
Sci Rep. 2024 Feb 19;14(1):4136. doi: 10.1038/s41598-024-54335-y.

本文引用的文献

1
Association between bone mineral metabolism and vascular calcification in end-stage renal disease.终末期肾病患者骨矿物质代谢与血管钙化的关系。
BMC Nephrol. 2022 Jan 3;23(1):12. doi: 10.1186/s12882-021-02652-z.
2
Histology and Immunohistochemistry of Radial Arteries Are Suggestive of an Interaction between Calcification and Early Atherosclerotic Lesions in Chronic Kidney Disease.慢性肾脏病中桡动脉的组织学和免疫组织化学表现提示钙化与早期动脉粥样硬化病变之间存在相互作用。
Medicina (Kaunas). 2021 Oct 24;57(11):1156. doi: 10.3390/medicina57111156.
3
Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association.
肥胖与心血管疾病:美国心脏协会科学声明
Circulation. 2021 May 25;143(21):e984-e1010. doi: 10.1161/CIR.0000000000000973. Epub 2021 Apr 22.
4
Association of Body Mass Index With Coronary Artery Calcium and Subsequent Cardiovascular Mortality: The Coronary Artery Calcium Consortium.体重指数与冠状动脉钙及随后心血管死亡率的关系:冠状动脉钙联盟。
Circ Cardiovasc Imaging. 2020 Jul;13(7):e009495. doi: 10.1161/CIRCIMAGING.119.009495. Epub 2020 Jul 14.
5
The bone-vessel axis in chronic kidney disease: An update on biochemical players and its future role in laboratory medicine.慢性肾脏病中的骨-血管轴:生化参与者的最新进展及其在检验医学中的未来作用
Clin Chim Acta. 2020 Sep;508:221-227. doi: 10.1016/j.cca.2020.05.023. Epub 2020 May 15.
6
RANKL biology: bone metabolism, the immune system, and beyond.核因子κB受体活化因子配体生物学:骨代谢、免疫系统及其他领域
Inflamm Regen. 2020 Feb 7;40:2. doi: 10.1186/s41232-019-0111-3. eCollection 2020.
7
The role of OPG/RANKL in the pathogenesis of diabetic cardiovascular disease.骨保护素/核因子κB受体活化因子配体在糖尿病心血管疾病发病机制中的作用
Cardiovasc Endocrinol Metab. 2018 May 16;7(2):28-33. doi: 10.1097/XCE.0000000000000144. eCollection 2018 Jun.
8
Positive Association of Serum Adipocyte Fatty Acid Binding Protein Level With Peripheral Artery Disease in Hemodialysis Patients.血清脂肪细胞脂肪酸结合蛋白水平与血液透析患者外周动脉疾病的正相关性。
Ther Apher Dial. 2020 Jun;24(3):300-306. doi: 10.1111/1744-9987.13431. Epub 2019 Oct 9.
9
Abdominal aortic calcification score can predict future coronary artery disease in hemodialysis patients: a 5-year prospective cohort study.腹主动脉钙化评分可预测血液透析患者的未来冠心病:一项为期 5 年的前瞻性队列研究。
BMC Nephrol. 2018 Nov 8;19(1):313. doi: 10.1186/s12882-018-1124-x.
10
Elevated Circulating Osteoprotegerin Levels in the Plasma of Hemodialyzed Patients With Severe Artery Calcification.严重动脉钙化的血液透析患者血浆中骨保护素水平升高。
Ther Apher Dial. 2018 Oct;22(5):519-529. doi: 10.1111/1744-9987.12681. Epub 2018 Jul 4.